Business Context and Reporting Period
Company: GlycoMimetics, Inc. (Note: Request metadata listed "Crescent Biopharma," but the filing text identifies the registrant as GlycoMimetics, Inc.)
Reporting Period: Fiscal year ended December 31, 2013
Business Overview: GlycoMimetics is a clinical-stage biotechnology company developing glycomimetic drugs to treat diseases involving carbohydrate biology. The company's lead candidate, GMI-1070 (rivipansel sodium), targets vaso-occlusive crisis (VOC) in sickle cell disease. Following the completion of a Phase 2 trial in April 2013, development and commercialization rights for GMI-1070 were transferred to Pfizer under a 2011 collaboration agreement. The company is advancing its second candidate, GMI-1271, for acute myeloid leukemia (AML).
Key Financial Metrics
| Metric (in thousands) | 2013 | 2012 |
|---|---|---|
| Revenue | $3,993 | $15,257 |
| Net Loss | $(10,606) | $3,656 (Net Income) |
| Research & Development Expenses | $11,701 | $9,438 |
| General & Administrative Expenses | $2,880 | $2,157 |
| Cash and Cash Equivalents (Year End) | $2,311 | $17,373 |
| Total Assets | $5,283 | $18,420 |
| Accumulated Deficit | $(63,275) | $(52,670) |
Liquidity: As of December 31, 2013, the company held $2.3 million in cash. Management estimated this would fund operations for at least 12 months, excluding potential milestone payments from Pfizer. The company completed an Initial Public Offering (IPO) in January 2014, raising approximately $57.4 million in net proceeds.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 74% to $4.0 million in 2013 from $15.3 million in 2012. This was due to the full recognition of the $22.5 million upfront payment from Pfizer by March 31, 2013. No milestone payments were earned in 2013.
- Return to Losses: The company reported a net loss of $10.6 million in 2013, reversing the net income of $3.7 million recorded in 2012 (which was driven by the Pfizer revenue recognition).
- Increased R&D Spend: R&D expenses increased 24% to $11.7 million, primarily driven by manufacturing and process development costs for GMI-1271 in preparation for an Investigational New Drug (IND) filing.
- Cash Burn: Cash and cash equivalents decreased by approximately $15.1 million during the year, reflecting a net cash outflow from operating activities of $15.5 million.
Guidance, Outlook, and Risks
Outlook:
- GMI-1070: Pfizer is responsible for Phase 3 development. Pfizer intends to commence a Phase 3 trial in the second half of 2014, pending internal governance approval. GlycoMimetics is eligible for a $35.0 million milestone upon the dosing of the first patient in Phase 3.
- GMI-1271: The company filed an IND in February 2014 and plans to initiate a Phase 1 trial in healthy volunteers in the second quarter of 2014, followed by trials in AML patients.
- Capital Needs: The company expects to incur significant losses for the foreseeable future and will require additional financing to fund operations beyond the next 12 months.
Risks and Contingencies:
- Dependence on Pfizer: Future revenue is heavily dependent on Pfizer's ability and willingness to advance GMI-1070. If Pfizer delays or terminates development, GlycoMimetics may not receive milestone payments.
- Development Risks: Clinical trials may fail to demonstrate efficacy or safety. The Phase 2 results for GMI-1070 showed positive trends but did not achieve statistical significance for the primary endpoint (time to resolution of VOC) using standard p-value thresholds, though they did show statistical significance for reduced opioid use.
- Liquidity Risk: The company has an accumulated deficit of $63.3 million and no products currently on the market. Failure to raise additional capital could force delays in development programs.
Key Facts for Investor Verification
- Revenue Recognition: Verify the accounting treatment of the $22.5 million Pfizer upfront payment, which was recognized over 1.5 years and fully recognized by Q1 2013.
- Phase 2 Statistical Significance: Review the specific p-values for GMI-1070 Phase 2 endpoints; while opioid use reduction was statistically significant (p=0.01), the primary endpoint (time to resolution) was not (p=0.192).
- Upcoming Milestones: Confirm the timeline for the GMI-1070 Phase 3 trial initiation (targeted H2 2014) and the associated $35 million milestone payment trigger.
- Capital Position: Assess the runway provided by the $2.3 million year-end cash balance plus the $57.4 million IPO proceeds raised in January 2014.
- University of Basel Agreement: Note the obligation to pay 10% of future Pfizer milestones and royalties to the University of Basel.